Cytek Biosciences, Inc. Net Income 2020–2025
Cytek Biosciences, Inc. reported $-66.54M of net income for fiscal 2025. That was 1005.3% lower than fiscal 2024. Compared with fiscal 2020, the change was -442.8%.
| Fiscal year | Net Income | Net margin | Change (YoY) |
|---|---|---|---|
| FY 2025 | $-66.54M | -33.0% | -1005.3% |
| FY 2024 | $-6.02M | -3.0% | +46.9% |
| FY 2023 | $-11.33M | -5.9% | -539.8% |
| FY 2022 | $2.58M | 1.6% | -14.9% |
| FY 2021 | $3.03M | 138.8% | -84.4% |
| FY 2020 | $19.41M | 2733.9% | — |
Source: Cytek Biosciences, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open CTKB 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Cytek Biosciences, Inc. reported $-66.54M of net income for fiscal 2025. That was 1005.3% lower than fiscal 2024. Compared with fiscal 2020, the change was -442.8%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Cytek Biosciences, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeCytek Biosciences, Inc. — frequently asked questions
What is Cytek Biosciences, Inc.'s net income?
Cytek Biosciences, Inc. (CTKB) reported net income of $-66.54M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Cytek Biosciences, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.